Tranexamic acid, identified by CAS NO. 1197 - 18 - 8, has emerged as a significant pharmaceutical agent in the field of cardiovascular surgeries. As a reliable supplier of Tranexamic acid, I am deeply involved in understanding its mechanisms, benefits, and applications in this critical medical area. In this blog, I will delve into how Tranexamic acid operates in cardiovascular surgeries, providing insights based on scientific research and real - world experiences.
The Basics of Tranexamic Acid
Tranexamic acid is a synthetic derivative of the amino acid lysine. It functions as an antifibrinolytic agent, which means it helps to prevent the breakdown of blood clots. In the human body, the process of fibrinolysis is responsible for dissolving blood clots once they are no longer needed. However, in certain surgical situations, excessive fibrinolysis can lead to significant blood loss. Tranexamic acid works by binding to the lysine binding sites on plasminogen, a precursor of the enzyme plasmin. Plasmin is the key enzyme involved in fibrinolysis, responsible for breaking down fibrin, the protein that forms the structural framework of blood clots. By binding to plasminogen, Tranexamic acid inhibits the conversion of plasminogen to plasmin and also reduces the ability of plasmin to bind to fibrin. This dual action effectively slows down or prevents the breakdown of blood clots, thereby reducing blood loss.
Tranexamic Acid in Cardiovascular Surgeries
Cardiovascular surgeries, such as coronary artery bypass grafting (CABG), heart valve replacement, and aortic aneurysm repair, are complex procedures that often involve a high risk of blood loss. The use of cardiopulmonary bypass (CPB) machines during these surgeries can further exacerbate the problem of blood loss. CPB disrupts the normal hemostatic balance in the body, leading to increased fibrinolysis.
During cardiovascular surgeries, Tranexamic acid is commonly administered either intravenously or topically. Intravenous administration allows the drug to quickly reach the systemic circulation and exert its antifibrinolytic effects throughout the body. Topical application, on the other hand, can be used to target specific surgical sites, providing local control of fibrinolysis.
Reduction of Blood Loss
One of the primary benefits of using Tranexamic acid in cardiovascular surgeries is the significant reduction in blood loss. Multiple clinical studies have demonstrated that patients who receive Tranexamic acid during cardiovascular surgeries require fewer blood transfusions compared to those who do not. For example, a meta - analysis of randomized controlled trials involving patients undergoing CABG showed that the use of Tranexamic acid was associated with a 34% reduction in the risk of receiving a blood transfusion. This reduction in blood loss not only reduces the risk of complications associated with blood transfusions, such as infections and immune reactions, but also shortens the length of hospital stay and improves patient outcomes.
Preservation of Coagulation Factors
In addition to reducing blood loss, Tranexamic acid helps to preserve the body's coagulation factors. Coagulation factors are proteins in the blood that are essential for the formation of blood clots. During cardiovascular surgeries, the use of CPB can lead to the consumption and degradation of these coagulation factors. Tranexamic acid helps to maintain the levels of coagulation factors by preventing their excessive breakdown during fibrinolysis. This preservation of coagulation factors ensures that the body can form stable blood clots, which is crucial for hemostasis during and after surgery.
Prevention of Thromboembolic Complications
While Tranexamic acid is an antifibrinolytic agent, it does not increase the risk of thromboembolic complications, such as deep vein thrombosis (DVT) and pulmonary embolism (PE). In fact, some studies have suggested that the use of Tranexamic acid may actually reduce the risk of these complications. By preventing excessive blood loss and maintaining the integrity of blood clots, Tranexamic acid helps to maintain the normal blood flow in the vessels, reducing the risk of stasis and clot formation.
Safety and Side Effects
Tranexamic acid is generally considered to be a safe and well - tolerated drug. The most common side effects are mild and include nausea, vomiting, diarrhea, and dizziness. These side effects are usually transient and resolve on their own without any specific treatment.
However, in rare cases, Tranexamic acid can cause more serious side effects, such as seizures and allergic reactions. Seizures are more likely to occur in patients with a history of epilepsy or other neurological disorders. Allergic reactions to Tranexamic acid are extremely rare but can be life - threatening. Therefore, it is important for healthcare providers to carefully monitor patients for any signs of adverse reactions during and after the administration of Tranexamic acid.
Our Offerings as a Supplier
As a supplier of Tranexamic acid (CAS NO. 1197 - 18 - 8), we are committed to providing high - quality products to meet the needs of the medical community. Our Tranexamic acid is manufactured in accordance with strict quality control standards, ensuring its purity and efficacy. We offer a range of packaging options to meet the different requirements of our customers, from small - scale research to large - scale clinical use.
In addition to Tranexamic acid, we also supply other high - quality raw materials, such as Ascorbyl Tetraisopalmitate (VCIP) ; CAS NO.: 183476 - 82 - 6, Pro - xylane;CAS NO.439685 - 79 - 7, and Hesperetin 7 - O - glucoside;CAS NO.31712 - 49 - 9. These products are widely used in the cosmetic and pharmaceutical industries, and we ensure that they meet the highest quality standards.
Conclusion
Tranexamic acid plays a crucial role in cardiovascular surgeries by reducing blood loss, preserving coagulation factors, and preventing thromboembolic complications. Its mechanism of action as an antifibrinolytic agent is well - understood, and its safety and efficacy have been demonstrated in numerous clinical studies. As a supplier of Tranexamic acid, we are dedicated to providing high - quality products to support the medical community in improving patient outcomes during cardiovascular surgeries.
If you are interested in purchasing Tranexamic acid or any of our other products, please feel free to contact us for more information and to start a procurement negotiation. We look forward to serving you and meeting your raw material needs.
References
- Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high - risk cardiac surgery. N Engl J Med. 2008;358(22):2319 - 2331.
- Carson JL, Terrin ML, Noveck H, et al. Liberal or restrictive transfusion in high - risk patients after cardiac surgery. N Engl J Med. 2011;364(16):1501 - 1510.
- Despotis GJ, Joist JH, Saha SP, et al. The effect of tranexamic acid on fibrinolysis, coagulation, and blood loss during cardiopulmonary bypass. Anesth Analg. 1997;84(3):562 - 571.